Briggs Morrison - Dec 17, 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Stock symbol
SNDX
Transactions as of
Dec 17, 2021
Transactions value $
-$319,920
Form type
4
Date filed
12/20/2021, 05:44 PM
Previous filing
Sep 21, 2021
Next filing
Jan 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $383K +35.2K +72.73% $10.90 83.5K Dec 17, 2021 Direct
transaction SNDX Common Stock Sale -$703K -35.2K -42.11% $20.00 48.3K Dec 17, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -35.2K -100% $0.00* 0 Dec 17, 2021 Common Stock 35.2K $10.90 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,305,602 options to purchase shares of common stock that are vested and immediately exercisable and a total of 339,083 options to purchase shares of common stock that have not yet vested.
F2 This option is fully vested.